Search clinical trials for: Busulfan and Fludarabine

Total 270746 results

Chinese PLA General Hospital

Recruiting

Allogenic CD19-targeting CAR-γδT Cell Therapy in r/r NHL

Non Hodgkin's Lymphoma

China
BGI, China
Sun Yat-sen University

Completed

Treatment of Advanced Solid Tumor With TSA-CTL(Tumor Specific Antigen-Induced Cytotoxic T Lymphocytes)

Solid Cancer

China
CTI BioPharma

Withdrawn

Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

Lymphoma | Leukemia

United States
Genta Incorporated

Completed

Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Leukemia

United States
St. Luke's Medical Center

Unknown

Vaccine Therapy With or Without Fludarabine in Treating Patients With Stage IV Kidney Cancer

Kidney Cancer

United States
Center for International Blood and Marrow Transplant...
National Marrow Donor Program

Recruiting

HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis (OPTIMIZE)

Lymphoma | Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myelofibrosis | Chronic Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Chronic Myeloid Leukemia | Acute Leukemia | Myeloproliferative Neoplasm | Pro-Lymphocytic Leukemia

United States
UNC Lineberger Comprehensive Cancer Center
Bellicum Pharmaceuticals; University Cancer Research Fund at Lineberger Comprehensive...

Recruiting

Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC

Head and Neck Cancer | Relapse | Refractory Cancer | Recurrent

United States
Otsuka Pharmaceutical Development & Commercialization...
Center for International Blood and Marrow Transplant Research

Completed

PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients

Lymphoma

United States, Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma

Refractory Plasma Cell Myeloma | Plasmacytoma | Recurrent Plasma Cell Myeloma | Plasma Cell Leukemia

United States
M.D. Anderson Cancer Center
Genentech, Inc.

Completed

Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline

Chronic Lymphocytic Leukemia

United States
Prof. Serge Leyvraz

Completed

Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma

Melanoma (Skin)

Switzerland
Technical University of Munich

Unknown

Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma

Lymphoma

Germany
M.D. Anderson Cancer Center
Bayer

Completed

Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Completed

Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma

Lymphoma

United States
St. Jude Children's Research Hospital

Completed

Stem Cell Transplantation With Identical Donors for Patients With Sickle Cell Disease

Sickle Cell Disease

United States
Cooperative Study Group A for Hematology

Unknown

Fludarabine and Cytarabine as Continuous Infusion Plus G-CSF Priming for Elderly Patients With Resistant AML

Acute Myeloid Leukemia

Korea, Republic of
National Heart, Lung, and Blood Institute (NHLBI)

Active, not recruiting

A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Novo Nordisk A/S

Completed

An Observational Study Investigating the Safety and Effectiveness of Repaglinide in Chinese Patients (SAFE)

Diabetes Mellitus, Type 2 | Diabetes

China
John Mascarenhas
National Cancer Institute (NCI); National Institutes of Health (NIH); Myeloproliferative...

Completed

Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis

Myelofibrosis

United States, Canada, Italy, Sweden
Fred Hutchinson Cancer Center

Recruiting

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders

Non-Neoplastic Hematologic and Lymphocytic Disorder

United States
Genzyme, a Sanofi Company

Terminated

AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone

Multiple Myeloma | Lymphoma, Non-Hodgkin's

United States
Pfizer

Completed

Linezolid for the Treatment of Infections Caused by Methicillin Resistant Staphylococcus Aureus in Japan

Infections, Nosocomial

Japan
Tongji Hospital
Nanjing IASO Biotechnology Co., Ltd.

Recruiting

Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System (CARTinNS)

Multiple Sclerosis | Autoimmune Diseases of the Nervous System | Autoimmune Diseases | Myasthenia Gravis | Neuromyelitis Optica Spectrum Disorder | Autoimmune Encephalitis | Idiopathic Inflammatory Myopathies | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Myelin Oligodendrocyte Glycoprotein... and other conditions

China
Inge Marie Svane

Withdrawn

T-cell Based Immunotherapy for Head and Neck Cancer

Head and Neck Cancer | Squamous Cell Carcinoma

Denmark
University Hospital Carl Gustav Carus

Completed

Early Allogeneic Blood Stem Cell Transplantation in High-risk Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

Germany
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Incyte Corporation

Active, not recruiting

JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

Primary Myelofibrosis | Secondary Myelofibrosis

United States
Fred Hutchinson Cancer Center

Withdrawn

Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation

Recurrent Hodgkin Lymphoma | Myelofibrosis | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Hematopoietic and Lymphoid System Neoplasm | Recurrent... and other conditions

United States
M.D. Anderson Cancer Center

Recruiting

Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances

Hematological Malignancy

United States
Hackensack Meridian Health

Completed

Stem Cell Transplantation for Sickle Cell Anemia

Sickle Cell Disease

United States
M.D. Anderson Cancer Center
Jazz Pharmaceuticals

Withdrawn

Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies

Hematologic Malignancy
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Personalized NK Cell Therapy in CBT

Recurrent Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Myelodysplastic Syndrome... and other conditions

United States
M.D. Anderson Cancer Center

Completed

Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL)

Leukemia

United States
M.D. Anderson Cancer Center
Bayer

Completed

FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Providence Cancer Center, Earle A. Chiles Research...
National Cancer Institute (NCI)

Completed

Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma

Melanoma (Skin)

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Withdrawn

Fludarabine and Cyclophosphamide Followed By LMB-2 Immunotoxin in Treating Patients With Hodgkin's Lymphoma

Lymphoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Terminated

Ex Vivo Expansion of Mafosfamide Purged CD34+ Cells in Patients With Acute Leukemia

Leukemia

United States
Nanfang Hospital of Southern Medical University
Peking University People's Hospital; Guangzhou First People's Hospital; Sun Yat-Sen... and other collaborators

Unknown

BUCY+VP-16 vs BUCY Conditioning Regimen for DLBCL Undergoing Auto-HSCT

Conditioning | Diffuse Large B-cell Lymphoma | Autologous Hematopoietic Stem Cell Transplantation

China
Abramson Cancer Center of the University of Pennsylvania
National Cancer Institute (NCI)

Completed

Chemotherapy and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia

Leukemia

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
University of California, Los Angeles
National Institute of Allergy and Infectious Diseases (NIAID); National Heart... and other collaborators

Completed

Autologous CD34+ Hematopoietic Stem Cells Transduced ex Vivo With Elongation Factor 1 Alpha Shortened (EFS) Lentiviral Vector Encoding for the Human ADA Gene

ADA-SCID

United States
University Hospital, Strasbourg, France

Unknown

Respiratory Side Effects of Busulfan High Dose Chemotherapy in a Pediatric Population

Signs and Symptoms, Respiratory

France
National Cancer Institute (NCI)
National Institute of Neurological Disorders and Stroke (NINDS)

Recruiting

Optimizing PTCy Dose and Timing

Hematologic Neoplasms | Graft Versus Host Disease

United States
St. Petersburg State Pavlov Medical University

Completed

Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe) (FluBuBe)

Myelodysplastic Syndromes | Lymphoblastic Lymphoma | Myeloproliferative Neoplasm | Leukemia, Acute Lymphoblastic | Myeloid Leukemia, Acute | Biphenotypic Acute Leukemia

Russian Federation
University of Rochester

Recruiting

Umbilical Cord Blood Transplantation From Unrelated Donors

Lymphoma | Myelodysplastic Syndromes | Multiple Myeloma | Solid Tumor | Acute Leukemia | Aplastic Anemia | Chronic Leukemia | Immune Deficiency Disorder | Congenital Hematological Disorder | Metabolism Disorder

United States
Memorial Sloan Kettering Cancer Center

Terminated

Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors

Hodgkin Lymphoma | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Acute Myeloid Leukemia (AML) | Chronic Myeloid Leukemia (CML) | Acute Lymphoid Leukemia (ALL)

United States
Masonic Cancer Center, University of Minnesota

Terminated

Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia

Leukemia

United States
University of Alabama at Birmingham

Terminated

Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies

Multiple Myeloma | Mantle Cell Lymphoma | Non Hodgkin's Lymphoma | CLL / SLL | Waldenstroms

United States
UNC Lineberger Comprehensive Cancer Center

Not yet recruiting

Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells

Ovarian Cancer | Epithelial Ovarian Cancer | Ovary Neoplasm | Recurrent

United States
M.D. Anderson Cancer Center
Sanofi

Completed

Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL

Leukemia

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Cellular Adoptive Immunotherapy in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma

Lymphoma

United States

Search clinical trials for: Busulfan and Fludarabine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kuwait

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations